AACR . PM01183 . Lurbinectedin Not Only Did Not Activate the Same Mechanisms of Resistance as Cisplatin in Ovarian Cancer Cells, but even Reversed the Resistance of these Resistant Cells to Platinum Drugs.

Session PO.ET04.05 "Lurbinectedin Reverses Platinum Dependent IRF1 Overexpression and Nuclear Localization" at AACR17 with AACR .